0ver the past 30 years, heparin has become the drug most commonly used to treat a variety of acute thrombotic disorders. Heparin reduces the incidence of recurrence while causing relatively few adverse reactions. However, the protection afforded by heparin against recurrent thrombosis is not complete, and the amount of the drug which can be administered is limited by the risk of serious bleedin...

Neonatal thromboembolism occurs with various predisposition and triggers. Early diagnosis of the thrombosis is challenging essential for therapeutic interventions. We herein report one newborn who presented transient patient arterial underwent Doppler received low molecular weight heparin (LMWH) subcutaneously. Newborns suspected having may need urgent surgical intervention along thrombolytic a...

The oral delivery of heparin is the preferred therapy in the treatment of patients with a high risk of deep vein thrombosis and pulmonary embolism. New conjugates of heparin and sodium deoxycholate were synthesized in order to enhance the heparin absorption in the GI tract. After oral administration of DOC-heparin, the concentration in anti-FXa assay was increased with increasing amount of coup...

In order to determine their value for estimating the heparin concentration in plasma, we established the relationship between test result and heparin concentration in plasma from various individuals, for five assays used with heparin treatment. Only assays which can be carried out routinely in clinical laboratories were considered. The thrombin time and the whole blood recalcification time give...

Heparin-induced thrombocytopenia (HIT) is an immune-mediated coagulation side effect of heparin therapy characterized by thrombocytopenia and by a paradoxical prothrombotic state following heparin exposure when thrombotic or thromboembolic events accurse, the condition is classified as Heparin-induced thrombocytopenia with thrombosis (HITT). We report a case of HITT with evidence of small-vesse...

I N 1949, Owren first noted a beneficial effect of heparin therapy in autoimmune hemolytic anemia.1 Dramatic therapeutic responses were subsequently reported by other investigators.26 However, neither the value nor the precise mechanism of action of this drug has been elicited in the treatment of autoimmune hemolytic anemia. We have evaluated the use of parenteral heparin in seven patients with...

Following the implementation of citrate anticoagulation for continuous renal replacement therapy, we evaluate its first year of use and compare it to the previously used heparin, to assess whether our patients benefit from the recently reported advantages of citrate. We retrospectively analysed 2 years of data to compare the safety and efficacy of citrate versus heparin. The results have shown ...

A patient with acute coronary syndrome scheduled for urgent coronary artery bypass grafting developed a profound thrombocytopenia during therapy with intravenous heparin and the glycoprotein IIb/IIIa inhibitor tirofiban. Heparin-induced thrombocytopenia and all other possible aetiologies were unlikely and the low platelet count had to be attributed to tirofiban. Anticoagulation during cardiopul...

Heparin-induced thrombocytopenia (HIT) is an immune-mediated disorder caused by the development of antibodies to platelet factor 4 (PF4) and heparin. The thrombocytopenia is typically moderate, with a median platelet count nadir of approximately 50 to 60 x 10(9) platelets/L. Severe thrombocytopenia has been described in patients with HIT, and in these patients antibody levels are high and sever...

UNLABELLED Heparin Induced Thrombocytopenia (HIT) is an adverse effect of heparin therapy with possibly devastating consequences. We present a case of HIT Type II. An in-depth review of HIT is presented, examining the important clinical symptoms and diagnostic indicators. The treatment of HIT is then discussed, with an emphasis on current therapies. An extensive literature review has been perfo...